SGEN should buy IMGN NOW and dominate the ADC market
SGEN is already the leader, but buying IMGN adds annual revs that will hit over $100MM maybe much more around $2015-2016, $200MM in cash, additional compounds in various stages of development, additional platform and partnership compounds with LLY, AMGN, Sanofi and Bayer (already working well with Roche, who owns most of T-DM1, super herceptin, which is close to approval. SGEN can get all that and more now for $18-20 in SGEN stock and cash, maybe pay out most of the IMGN cash in the deal. Forgot to mention cost cutting, there are some IMGN exect that need to go ASAP. It's a smart deal IMO